Bavarian Nordic and AZ combine cancer jab with durvalumab AstraZeneca (AZ) and Bavarian Nordic (BN) combine BN’s cancer vaccine CV301 and AZ’s PD-L1 checkpoint blocker durvalumab in an investigator-sponsored trail to check synergistic effects in patients with … more ➔
EMA recommends two orphan drugs for approvalThe European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended three medicines, two thereof orphan drugs, at its February 2018 meeting. more ➔
Bioeconomy: Bringing in the publicEverybody wants green production. Bioeconomy progress, however, must become more visible to consumers and let the civil society get involved to ensure socially robust innovation and perception, according … more ➔
New Screening method for Antibiotic Discovery Pipeline A new method that determines the mode of action underlying antimicrobial compounds could help overcome a major stumbling block in the ongoing effort to discover new antibiotics. Using it, reseachers … more ➔
Cullinan Oncology partners with MAB DiscoveryVirtual oncology company Cullinan Oncology, LLC has selecteed monoclonal antibody provider MAB Discovery GmbH (Neuried) to develop the first candidate of a target portfolio of 8-10 novel … more ➔
Locking malaria parasites into red blood cellsUK researchers headed by Michael Blackman have found out that a proteolytic cascade regulates release of merozoites of the human malaria parasite Plasmodium falciparum from host red blood cells. … more ➔
PharmaMar in licence deal with Seattle GeneticsSpanish specialist for sea-derived synthetic oncology drugs, PharmaMar SA, has inked a licence agreement with US antibody drug conjugate (ADC) company Seattle Genetics Inc. PharmaMar will provide fully-synthetic … more ➔
Roche to pay US$1.9bn for Flatiron HealthIn a strategic acquisition, Roche has completed its capabilities to use Big data to build new business cases in digital diagnostics solutions and personalised healthcare. The pharma major agreed to pay … more ➔
Santhera licenses CF drug from Polyphor Santhera Pharmaceuticals has licenced the inhaled neutrophil eleastase blocker POL6014 from Polyphor Ltd for CHF6.5m upfront and CHF121m in potential milestones. more ➔
AML: Sorafenib boosts graft-versus-leukemia activityCo-administration of an allogenic blood stem cell transplant and sorafenib cured AML patients refractive to chemotherapy and stem cell transplants alone, oncologists report in Nature Medicine. more ➔
